Chetomin, a Hsp90/HIF1α pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells

• Published in: Cancer biology & therapy 2020-08, Vol.21 (8), p.698-708
• Main Authors: Min, Shengping, Wang, Xiaoxu, Du, Qianyu, Gong, Huiyuan, Yang, Yan, Wang, Tao, Wu, Nan, Liu, Xincheng, Li, Wei, Zhao, Chengling, Shen, Yuanbing, Chen, Yuqing, Wang, Xiaojing
• Format: Article
• Language: English
• Subjects: cancer stem cells; Chetomin; heat shock protein; lung cancer; Research Paper
• ISSN: 1538-4047; 1555-8576
• DOI: 10.1080/15384047.2020.1763147

Non-small cell lung cancer (NSCLC) remains recalcitrant to effective treatment due to tumor relapse and acquired resistance. Cancer stem cells (CSCs) are believed to be one mechanism for relapse and resistance and are consequently considered promising drug targets. We report that chetomin, an active component of Chaetomium globosum, blocks heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway activity. Chetomin also attenuated sphere-forming, a stem cell-like characteristic, of NSCLC CSCs (at ~ nM range) and the proliferation of non-CSCs NSCLC cultures and chemoresistant sublines (at ~ μM range). At these concentrations, chetomin exerted a marginal influence on noncancerous cells originating from several organs. Chetomin markedly decreased in vivo tumor formation in a spontaneous Kras LA1 lung cancer model, flank xenograft models, and a tumor propagation flank implanted model at doses that did not produce an observable toxicity to the animals. Chetomin blocked Hsp90/HIF1α pathway activity via inhibiting the Hsp90-HIF1α binding interaction without affecting Hsp90 or Hsp70 protein levels. This study advocates chetomin as a Hsp90/HIF1α pathway inhibitor and a potent, nontoxic NSCLC CSC-targeting molecule.